increased significantly (1). Despite several large-scale epidemiological studies, there remain unanswered questions pertaining to regional differences in the pattern of substance misuse among adolescents. Accurate information on the magnitude of this problem is crucial for allocation of limited resources.
In a pilot study, we gathered data on adolescents aged 12 to 18 years (minus 1 day) referred to inpatient and outpatient services at the Division of Child and Adolescent Psychiatry, Hotel Dieu Hospital, Kingston, Ontario. These patients had completed the substance use questionnaire (SUQ) appropriately and had given informed consent. We developed the SUQ based on the adult version. It includes questions about the patient's sex and age, as well as about the frequency, quantity, and type of substance used (2, 3) . The SUQ also includes questions formulated from the DSM-IV criteria for substance abuse disorder and substance dependence disorder. To ensure that the patients understand the questionnaire, its language is consistent with Grade 8 reading level. The questionnaire was administered by the staff at the inpatient unit and (or) by the intake secretary in the outpatient service. A package including the informed consent form, the SUQ, and 2 envelopes was prepared for each patient. The patients were given information about the study and reassured of its anonymity. If, after reading the questionnaire, the patients decided to participate and were aged 16 years or over, they signed the consent form and completed the questionnaire. When patients were younger than age 16 years, their legal guardian was required to sign the consent form before they participated. Upon completion, patients placed the questionnaires in separate envelopes, sealed them, and returned them to the staff.
Preliminary data on 15 adolescent psychiatric outpatients and 34 inpatients show a preponderance of adolescent girls in both groups. This can be explained by the overall higher rates of psychiatric admissions and outpatient clinic attendance for female patients. Further, our data show strong evidence of an association between alcohol and cigarettes, cannabis and cigarettes, and especially, alcohol and cannabis. The association of alcohol and cannabis is statistically significant in both in-and outpatient groups. At the time of writing this letter, we have gathered further data on the above population and added pediatric outpatients as a comparison group. The final analysis on all 3 clinical sample populations is in process and will be reported in the near future. Mrs A, a 42-year-old white woman with paranoid schizophrenia, was treated for 4 years with fluphenazine decanoate 25 mg intramuscularly (IM) every 4 weeks. Owing to mild depression, the medication was changed to zuclopenthixol decanoate 50 mg IM every 4 weeks. She did not receive any other drugs and had no extrapyramidal side effects (EPSEs). After 10 months of zuclopenthixol treatment, she complained of paresthesias on the right side of her face and numbness of the tongue. Clinically, we observed mild oral dyskinesia, and the zuclopenthixol was stopped. One month later, Mrs A presented with right-side peripheral facialis palsy that had occurred overnight after 3 weeks of continued paresthesias. The consultant neurologist found a right-side mandibular deviation without any other neurological signs. There were no signs of infection or other medical condition, and her EEG and CT scans were normal. Owing to suspected preexisting dystonia, biperiden 2 mg 3 times daily and clozapine 25 mg 3 times daily were prescribed; however, the palsy did not resolve. Three years later, the mandibular deviation was severe and caused marked facial asymmetry. Because we suspected tardive dystonia, botulinus toxin was injected into the right pterygoid muscle, with almost no effect. The procedure was not repeated. To date, 10 years later, the neurological condition is unchanged. Mrs A is currently taking olanzapine 20 mg daily and is in stable remission. She was referred to a maxilofacial surgeon, who found a spastic right facialis palsy. She refused the proposed extraction of all teeth and a corrective dental prosthesis.
To our knowledge, this is the first report of nerve palsy in a patient taking zuclopenthixol. Transient palsy has been reported after intoxication with several antipsychotics (1) or after drug-induced extrapyramidal rigidity (2). Our patient was taking relatively low dosages of antipsychotics without any EPSEs. In another case, dystonia presenting as Bell's palsy (3) occurred in a patient after taking prochlorperazine and quickly resolved after taking diphenhydramine. Anticholinergics did not benefit our patient. Three cases of bilateral facialis palsy and 4 more cases of sensory neuropathy have been reported in perazine-treated patients after intensive sun exposure (4) . Since the palsy occurred in our patient in November, sun exposure was not likely the precipitating factor. Interestingly, all mentioned cases involved phenothiazines, while zuclo-penthixol is chemically a tioxanthene.
Palsy probably develops in conjunction with antipsychotic-induced EPSEs. It remains to be seen whether novel atypical antipsychotics, which cause few or no EPSEs, are safer regarding this rare but debilitating complication.
Milan Licina, MD, PhD Rok Tavcar, MD, PhD Ljubljana-Polje, Slovenia
Recognizing Complicated Grief in Clinical Practice
Dear Editor:
Losing a significant person through death is a common experience. Recently, we conducted a study that examined the prevalence of death losses and complicated grief among psychiatric outpatients at 2 hospital clinics (1). We found that 55% of patients reported a death loss; of this group, 60% met criteria for complicated grief. These figures suggest that as many as one-third of the patients seen at outpatient clinics may meet criteria for complicated grief.
Although not recognized as a distinct disorder in the DSM-IV-TR (2), there is reasonable consensus in the field about what constitutes complicated grief. A person experiencing complicated grief often reports preoccupation with, yearning for, and searching for the deceased. Intrusive images, ideas, memories, or recurrent dreams or nightmares associated with the lost person are also frequently reported. Active avoidance of thoughts, communications, or actions associated with the loss are common. Despite the unpleasant nature of these symptoms, patients often seem reluctant to give them up.
The symptoms' debilitating effect often interferes with daily functioning-also a criterion for other disorders, most notably major depression. Despite their frequent comorbidity, we have demonstrated that complicated grief and depression can be clearly distinguished (3).
Clinicians must also be aware of the time since the loss. To avoid pathologizing a normal, acute bereavement response, experts suggest that symptoms must persist for several months after the loss before a diagnosis of complicated grief is considered.
Medical and psychiatric training often devote little time to the recognition of complicated grief. This may lead to its lack of detection. Identifying complicated grief is also made difficult by the fact that patients may not be aware of the causal connection between a significant loss and present difficulties. Therefore, clinicians must consider the etiology of symptoms as well as their phenomenology. This task can be assisted by familiarity with the factors placing individuals at risk for complicated grief and with the indications that the syndrome may be present.
Consistently reported risk factors include loss through suicide; loss of a child or partner; sudden, unexpected, or untimely deaths; lack of social support; and a problematic relationship with the deceased. One of the clearest indicators of complicated grief is the patient's inability to speak about the loss with composure, even though a long time may have elapsed since the loss. Another indicator concerns anniversary reactions. The clinician may discover that the patient's symptoms occur at specific dates or times of the year. Alternatively, despite the apparent importance of a loss, there may be a total absence of distress. The affect of the patient may change dramatically when the loss is further explored.
Several resources can help those who are having difficulty adjusting to a death loss. Referral is based on the severity of the individual's maladjustment. For those with mild-to-moderate difficulties, community peer-support groups or counselling may be appropriate. For those with more severe difficulties, specialized psychiatric care may be required. Antidepressant medications have shown a modest effect on complicated grief symptoms (4), and group psychotherapy has been found to be highly effective (5) .
